Perhexiline - Heart Metabolics

Drug Profile

Perhexiline - Heart Metabolics

Alternative Names: Perhexiline maleate; WSM 3978 G

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HMBL Limited
  • Developer Heart Metabolics Limited
  • Class Antihypertensives; Cyclohexanes; Ischaemic heart disorder therapies; Piperidines; Small molecules
  • Mechanism of Action Calcium channel antagonists; Carnitine O-palmitoyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiomyopathies
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypertrophic cardiomyopathy

Most Recent Events

  • 26 Aug 2017 Efficacy and pharmacodynamics data from a phase I trial in healthy volunteers presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2017)
  • 02 Aug 2017 Heart Metabolics Limited terminates a phase II trial due to lack of efficacy in Hypertrophic cardiomyopathy in USA (PO) (NCT02862600)
  • 12 Jul 2017 Heart Metabolics withdraws a phase III trial prior to enrolment for Hypertrophic cardiomyopathy in USA due to lack of efficacy in a preceding study (PO) (NCT02431221)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top